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Individual differences in response to addictive substances may provide important clues to the mechanisms underlying
drug action, addiction, reward, and reward-related disease states. Early psychoneuroendocrinological studies have led
to the distinction of responders and nonresponders upon µ opiate receptor agonist administration. The systematic
analysis of the gene encoding the µ opiate receptor reveals abundant DNA sequence diversity, suggesting numerous
individually different forms of the gene. The present work illustrates the challenges of establishing complex geno-
type-phenotype relationships in the presence of high natural sequence variation, and provides some preliminary solu-
tions. Progress in the future is expected to come from whole systems analysis-based approaches, integrating variation
in all genes in all pathways.     
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:471-475.
The examination of human individual differences at all lev-
els of biological and phenotypic analysis will provide
important insights into the mechanisms underlying com-
plex traits.In particular,individual differences in response
to addictive substances may help to elucidate the mecha-
nisms underlying drug action, addiction, reward, and
reward-related disease states.“The individual”has,both
conceptually and concretely,been banned for far too long
from approaches to scientific investigation.At the heart of
endeavours to describe the functions and dysfunctions of
“the”organism was the determination of mean values,as
the averages of all individual values,and a standard error
that indicated the extent of deviation of the individual val-
ues from the “mean,”or “true”value.In other words,indi-
vidual variation was conceived exclusively as the result of
errors introduced in the process of measurement.At its
extreme,the mean value would describe an effect that did
not apply to any of the individuals studied. In this para-
digm,the approach to gaining insight into the mechanisms
underlying disease was based on the comparison of mean
values between patients and healthy controls,usually result-
ing from a one-off experiment.Thus, in order to test an
involvement of the opioidergic system in depressive disor-
ders, we compared neuroendocrine and behavioral
responses to the highly potent µ opiate receptor agonist
fentanyl,both in patients and controls.At the time,insights
into central receptor functions in humans were to be gained
only indirectly:pharmacological substances known to inter-
act with central nervous system receptors were adminis-
tered intravenously,and receptor-mediated effects such as
the release of hormones were measured peripherally as
indicators of receptor function.
Evidence for individual variation in response to
µ opiate receptor agonist administration
In order to prepare the ground for such an opiate challenge
in patients, we had performed, first, a systematic dose-
response study in normal volunteers.Doses of 0.1,0.2,and
0.25 mg fentanyl per 70 kg body weight were tested in a
randomized design at 3-week intervals,and specific dose-
related effects on the release of prolactin,growth hormone,
cortisol,catecholamines,and euphoric responses were able
to be demonstrated.In particular,this work presented the
first experimental evidence of a dose-dependent increase
in the rewarding properties of fentanyl.A dose of 0.2 mg472
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per 70 kg body weight proved suitable to reliably induce an
opiate-specific effect without causing adverse side effects
or stress reactions.
1-4When this dose was administered to
depressive patients in a one-off experiment, both mean
growth hormone and euphoric response to fentanyl was
significantly reduced compared with normal controls.
5This
suggested a possible involvement of µ opioid receptor-
related function in depression.
Most interestingly,when the individual responses underly-
ing the mean euphoric effect of fentanyl in normal volun-
teers (Figure 1A) were examined,a remarkable individual
variation was observed (Figure 1B). One fourth of the
“normal”volunteers did not exhibit any euphoric reaction,
or showed a decrease in well-being.Evaluation of euphoric
responses was based on:(i) application of visual analogue
scales;(ii) documentation and classification of all sponta-
neous verbal reports of the volunteers;and (iii) detailed
documentation of all observations during the experiment
by two experts.These different instruments were found to
be highly concordant,allowing unambiguous classification
of the volunteers’ behavioral patterns. Moreover, these
individual response patterns proved consistently evocable
over time,ie,in the course of repeated applications of fen-
tanyl.
2,6This suggested that individual responsiveness to this
µ opiate receptor agonist might represent a trait variable,
and that “normal”individuals might be classified into drug
responders and nonresponders (Figure 1C).
2 Similar obser-
vations were made upon administration of morphine.
2This
suggests that a subgroup of individuals may not be disposed
to experience euphoria upon exposure to addictive drugs.
Absence of euphoric response was not correlated with a
blunted growth hormone release upon application of fen-
tanyl or morphine,suggesting that different (opioid) mech-
anisms might be involved in mediation of rewarding prop-
erties of addictive substances.Thus, tracking a potential
genetic basis underlying nonresponse may provide impor-
tant clues the mechanisms involved in the development of
addiction,or in a more general way the personal disposi-
tion to experience reward,and potentially lead to targets
of intervention.
Evidence for abundant DNA sequence 
variability in the gene encoding the 
human µ opiate receptor
Major advances in human molecular genetics in the late
1980s led to the cloning of numerous genes encoding
Copyright © 2007 LLS SAS. All rights reserved
Figure 1. Euphoric responses to µ opiate receptor agonist administration.
A) Visual analogue scale (VAS) scores as mean values before and up to 60
min after administration of 0.2 mg fentanyl/kg; 0 mm = very unpleasant feel-
ings; 100 mm = extremely positive feelings
B) Visual analogue scale scores presented as individual values before and up
to 60 min after administration of 0.2 mg fentanyl/kg
C) Classification of individual VAS scores into two response types, euphoric
responders / nonresponders. 
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pharmacologically characterized receptors.This allowed
in principle to address the role of receptors in disease and
individually different drug response for the first time at
the most basic level,that is,DNA sequence information.
If DNA sequence differences in the receptor gene were
identified that were correlated with the individual phe-
notype in question,this could provide important clues on
underlying receptor dysfunction and its nature.Since it
is the entire gene and its encoded protein that act as the
units of function which potentially affect a phenotype
(and ultimately allow the first conclusions on disease
mechanisms), it appeared mandatory to analyze the
entire sequences of the individual genes,including their
regulatory and critical intronic sequences.This required
DNA sequence analyses at a previously unprecedented
scale,in the Megabase range.Thus,we developed a pow-
erful technique to perform comparative candidate gene
sequencing in large numbers of patients and controls,
“Multiplex Polymerase Chain Reaction (PCR)
Sequencing.”In principle,this technology allowed pro-
cessing multiple (up to 55) sequencing reactions simul-
taneously in one reaction tube, increasing throughput
accordingly.As a second prerequisite,we generated sig-
nificant information on the genomic organization of the
human µ opiate receptor gene,extending the previously
cloned complimentary DNA (cDNA) sequence infor-
mation
7 significantly.We determined several kb of 5’ reg-
ulatory region,identified a number of potential binding
sites for transcriptional regulatory factors, and cloned
critical intronic sequences.
8
These lines of research and technology development
were combined to conduct the first systematic and to
date most comprehensive analysis of DNA sequence
variation in the human µ opiate receptor gene
(OPRM1).
9 In a total of 250 individuals with a pheno-
type of severe substance (heroine/cocaine dependence
and controls from two major populations, African-
Americans and European-Americans, abundant DNA
sequence diversity was revealed (Figure 2). Regarding
the nature and distribution of sequence variation in
OPRM1, a total of 43 biallelic variants were identified.
Clearly, the density of variants was higher in the 5’ reg-
ulatory and untranslated regions than in the coding
regions, where six variants, five of which affect the
encoded protein,were found.Functional analyses of sev-
eral of these mutations in the coding were performed,
characterizing in particular modification of receptor
density and signaling (Figure 3).
10 Moreover, the influ-
ence of allelic variation in the 5’ region on regulation of
OPRM1 transcription was analyzed in a first study.
11
Figure 2. Polymorphic spectrum of the OPRM1 gene. The 6968 bp genomic reference sequence is presented as baseline; base pair coordinates relative to the
translation start site are given. Sequences are drawn to scale, which is indicated. All gene variants are specified by position numbers and nucleotide
variations (substitutions, insertions and deletions) according to mutation nomenclature. Those sites marked by an asterisk have been included in the
haplotype analysis.
Reproduced from ref 9: Hoehe MR, Köpke K, Wendel B, Flachmeier C, Kidd KK, Berrettini WH, Church GM. Sequence variability and candidate gene analysis in complex
disease: association of Ì opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;19:2895-2908. Copyright © IRL Press at Oxford University
Press 2000474
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Multiple individually different forms of the
human µ opiate receptor gene: relationship to
gene function and phenotype
The given sequence variability gives rise to numerous indi-
vidually different forms of the OPRM1 gene.It is essen-
tial in diploid organisms to determine the specific combi-
nations of given gene sequence variants for each of the
chromosomes defined as haplotypes. Because current
experimental methods to determine the molecular haplo-
types are still too labor- and cost-intensive,statistical tech-
niques were applied at this stage to predict these.In the
group of African-American substance-dependent individ-
uals and controls,a total of 52 different haplotypes were
distinguished (Figure 4A).
9,12These occurred at different
frequencies in the population,as illustrated in Figure 4B.
The five most frequent haplotypes,nos 43,14,4,24,and 7
were common to both substance-dependent individuals
and controls and constituted 66% to 73% of all haplo-
types.An additional four of less frequent haplotypes were
predicted, and a large number (43) of rare haplotypes
occurring at frequencies <1% amounted to a total of 20%
of all haplotypes.Thus,we will have to abandon Mendel’s
two-allele concept of a gene,which implicated existence of
both a predominant “wild type”and various mutant forms.
The picture exemplified at the model of OPRM1 appar-
ently applies,in view of our more extended candidate gene
analyses,to at least one third of all genes studied.
13Allelic
complexity in candidate genes may be large,and pose par-
ticular challenges to the analysis of genotype-phenotype
relationships,particularly in the situation of complex traits.
At first sight,such multiplicity of gene forms seems irrec-
oncilable with the assumption of dichotomous traits such
as health and disease,or drug response and nonresponse.
Moreover,the number of different haplotypes is unfeasi-
bly large,so that the power is not sufficient to detect an
Figure 4. The human µ opiate receptor study.  A. The multiplicity of haplo-
types. The polymorphic sites are specified by positions 1–25, marked
by an asterisk in Figure 2; 1, identical with the reference sequence;
2, different from the reference sequence. B. Distribution of haplo-
types. Haplotype frequencies are given in percentages, different
haplotypes are color-coded and correspond to the haplotypes
marked in A.
Reproduced in part from ref 12: Hoehe MR. Haplotypes and the systematic
analysis of genetic variation in genes and genomes. Pharmacogenomics.
2003;4:547-570. Copyright © Future Medicine Ltd 2003
Figure 3. Site-directed mutagenesis of amino acid residues of OPRM1. A
schematic representation of the putative seven transmembrane
domain topology of the receptor is shown. Polymorphisms that
affect protein sequence are indicated, and the mutations examined
highlighted.
Reproduced from ref 10: Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C,
Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the
human µ-opioid receptor severely impairs receptor signaling. J Biol Chem.
2001;276:3130-3137. Copyright © American Society for Biochemistry and
Molecular Biology 2001475
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association with any single haplotype.This will require
novel approaches to cope with the multiplicity of haplo-
types.An appropriate approach seems the classification of
haplotypes into functionally related (ideally functionally
equivalent) ones based on sequence-structure-function
similarity.Once a classification has been derived,the hap-
lotype frequencies of cases and controls in the different
classes can be compared.By this approach,the multiplic-
ity of haplotypes could be condensed to two functionally
related categories,one of which was more frequent in sub-
stance-dependent individuals.
9 Common to this category
was a characteristic pattern of sequence variants located
in the 5’ regulatory region,reflecting a specific constella-
tion of putative transcription regulatory motifs that may
confer different regulatory properties.
9,12Taken together,
this analysis at the gene level demonstrates a remarkable
gene sequence and haplotype diversity, the rule rather
than the exception for the majority of candidate genes.
This work provides,moreover,an example of approaches
that can be successfully applied to establish complex geno-
type-phenotype relationships against a background of high
natural genome sequence diversity.
Perspectives
Observed diversity presents challenges to the traditional
views of the concept of “a”gene with far-reaching impli-
cations on the analysis of “gene”-“function” relation-
ships.
13,14 Classical single mutation analysis no longer
appears appropriate.The units of functional analysis must
be the entire individual sequence of haplotypes,involving
potentially abundant variation in all regulatory,coding,and
intronic sequences.Analysis will include the spectrum of
haplotypes existing in a population,and the pairs of hap-
lotypes existing in each individual.We have now deter-
mined in a first comprehensive study the molecular hap-
lotypes of a key candidate gene in hundreds of individuals,
confirming the existence of multiple individually different
forms of a gene at the molecular level (Hoehe et al, in
preparation).This work provides at the same time knowl-
edge of the concrete molecular templates to allow dissec-
tion of what may be an entire spectrum of functions
underlying molecular gene diversity.
At this stage,individual variation and its functional impli-
cations have been addressed at the level of a single gene
only.However,this is integral part of an entire network of
genes as a higher-level functional unit;multiple individual
molecular haplotypes interact to produce a common out-
put signal.Thus,progress in the future is expected to come
from whole systems analysis-based approaches,
13 integrat-
ing individual variation in all genes involved in all path-
ways of relevance.This will prepare the basis for “person-
alized”medicine in its true sense. ❏
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